Read Trending Stories
- » Ultimate Market Recap: Talbots Tanks, Facebook Fiasco Continues
- » Are Facebook Losses Bigger Than Initially Thought?
- » Consumer Business Recap: Toyota Needs Emerging Markets, Wal-Mart's Express Update
- » Consumer Biz Recap: Talbots CRASHES HARD, Time Warner Eyes Sports Website
- » Your Cheat Sheet to Apple's Week of Stock Moving News
Today's Trending Stocks
Click a Company to Research Now:
- Bank of America (BAC)
- Apple . (AAPL)
- Facebook (FB)
- AT&T (T)
- Nokia (NOK)
- Delcath Systems (DCTH)
- Mentor Graphics Corp (MENT)
- Complete Genomics (GNOM)
REMICADE, made by Merck (NYSE:MRK), has been used in the treatment of inflammatory bowel disease for more than 12 years in the EU. Now, the Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a positive opinion recommending the use of REMICADE in the treatment of severely active ulcerative colitis in pediatric patients ages 6 to 17 years, who have had an inadequate response to conventional therapy, according to Merck. REMICADE will be the first and only biologic therapy approved in the EU for the treatment of pediatric ulcerative colitis, upon receipt of the corresponding Commission Decision.
Merck, denying any wrongdoing, will pay up to $36.5M to settle all of its Vioxx lawsuits in Canada, with the minimum payment expected to be no less than $21.6M, according to the Associated Press.
Get Your FREE Special Report: 4 Things You Must Know About the US Economy Now!
Do You Want More Profits? Wall St. Cheat Sheet Premium newsletter subscribers have been crushing the markets with winning stock picks.
Click here now for your FREE trial to our acclaimed flagship newsletter:
